Drug intelligence / Profile preview

FORC3

Development stage: Unknown
Lead developer: Axitan
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Oral

Overview

FORC3 is a biologic feed additive developed by Axitan Limited for use in poultry and other livestock to control *Clostridium perfringens*, the causative agent of necrotic enteritis. The product is a GRAS (Generally Recognized as Safe)-affirmed dried powder formulated by combining specific endolysin enzymes with fatty acids and microalgae. FORC3 functions by enzymatically destroying the cell walls of *Clostridium perfringens* before the bacteria can colonize the bird's gut, providing an antibiotic-free alternative for pathogen management. It has demonstrated efficacy in reducing early-life mortality and improving growth performance metrics in poultry flocks.

Brand names: FORC3FORC-3FORC 3

Targets

CP-PGN (Clostridium perfringens peptidoglycan)

Beyond the preview

Go deeper on FORC3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FORC3.

Explore the full profile